Cerus to Present at the 2018 Stephens NY Investment Conference
November 02 2018 - 8:30AM
Business Wire
Cerus Corporation (Nasdaq:CERS) announced today that William
‘Obi’ Greenman, Cerus’ president and chief executive officer, and
Kevin Green, Cerus’ vice president, finance and chief financial
officer, are scheduled to present a corporate update at the 2018
Stephens NY Investment Conference at 9:45 a.m. ET on Thursday,
November 8, 2018.
A live webcast of the presentation will be available from the
Investor Relations page of the Cerus web site at
http://www.cerus.com/ir. A replay will be available for
approximately two weeks following the completion of the event.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in
the field of blood transfusion safety. The INTERCEPT Blood System
is designed to reduce the risk of transfusion-transmitted
infections by inactivating a broad range of pathogens such as
viruses, bacteria and parasites that may be present in donated
blood. The nucleic acid targeting mechanism of action of the
INTERCEPT treatment is designed to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile
virus and bacteria, as well as emerging pathogens such as
chikungunya, malaria and dengue. Cerus currently markets and sells
the INTERCEPT Blood System for both platelets and plasma in the
United States, Europe, the Commonwealth of Independent States, the
Middle East and selected countries in other regions around the
world. The INTERCEPT Red Blood Cell system is in clinical
development. See http://www.cerus.com for information about
Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181102005093/en/
Cerus CorporationTim Lee, 925-288-6137Investor Relations
Director
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Apr 2024 to May 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From May 2023 to May 2024